List view / Grid view
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
6 June 2012 | By Phenomenex Inc
Phenomenex Inc., introduces Yarra™...
5 June 2012 | By Catalent Pharma Solutions
Completion of a newly renovated aseptic fill-finish manufacturing facility announced...
5 June 2012 | By Merck
Ridaforolimus is an investigational oral mTOR inhibitor...
5 June 2012 | By Abbott
Abbott have announced the initiation of a pivotal Phase 3 clinical trial...
5 June 2012 | By Abbott
One in three adults doesn’t obtain all of the daily nutrients they need to support optimal health...
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…
4 June 2012 | By Gerresheimer
Gerresheimer will be showcasing innovative solutions for the pharma industry at CPHI China, which takes place in Shanghai from June 26 to 28...
4 June 2012 | By
Phase III studies of single agent therapy in metastatic melanoma with BRAF V600 mutations meet primary endpoints...
4 June 2012 | By Eli Lilly and Company
Overall survival data from PARAMOUNT study submitted to FDA...
4 June 2012 | By Eli Lilly and Company
Eli Lilly and Company announced results of a Phase II trial evaluating ALIMTA®...
4 June 2012 | By Boehringer Ingelheim
LUX-Lung 3 results highlighted at the official ASCO Press Conference...
1 June 2012 | By Life Technologies
Integrated sample preparation and real-time PCR assay for the quantitation of E. coli host cell DNA...
Starting on 1 June 2012, Beat In-Albon will join Lonza as COO of the Life Science Ingredients Sector and become a member of the Management Committee, replacing Harry Boot. Beat In-Albon brings broad industry experience to his role, having worked for Lonza already from 1983-2006, where he was Head of…
1 June 2012 | By GlaxoSmithKline
GSK has clearance under the U.S. anti-trust laws to acquire HGS...
